Advertisement

Topics

Flex Pharma Initiates ALS Phase II Trial With FLX-787 In U.S.

20:00 EDT 31 Jul 2017 | BioSpace

-- Development of FLX-787 for ALS under Fast Track Designation -- BOSTON--(BUSINESS WIRE)--

Original Article: Flex Pharma Initiates ALS Phase II Trial With FLX-787 In U.S.

NEXT ARTICLE

More From BioPortfolio on "Flex Pharma Initiates ALS Phase II Trial With FLX-787 In U.S."

Quick Search
Advertisement